{"changes":[{"companyHref":"/c/terremotobiosciences-org","date":"2026-09-25","documentUrl":null,"domain":"terremotobiosciences.org","fact":"latest round","name":"Terremoto Biosciences, Inc.","new":{"amountUsd":41000000,"date":"2026-04-10","lead":null,"type":null},"old":{"amountUsd":41000000,"date":"2026-04-10","lead":null,"type":"seed"},"publisher":"sec-edgar","reason":null,"retrievedAt":"2026-05-08","slug":"terremotobiosciences-org","status":"attributed","url":"https://whoraisedwhat.com/c/terremotobiosciences-org"}],"country":"US","description":"Terremoto Biosciences is a covalent drug-discovery company creating selective small molecules that covalently bind lysine, found in nearly every protein. It targets oncology and rare disease, including undruggable targets, with a lead AKT1 inhibitor in the clinic. Its edge is lysine-based covalency beyond the cysteine residues older drugs use.","domain":"terremotobiosciences.org","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotechnology","investors":[],"lat":37.65354,"lng":-122.416866,"location":"SOUTH SAN FRANCISCO, CA","name":"Terremoto Biosciences, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":41000000,"currency":"USD","date":"2026-04-10","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":null,"url":null}],"slug":"terremotobiosciences-org","sources":[{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"terremotobiosciences.org","retrievedAt":"2026-05-08","status":"self-reported","url":"https://terremotobiosciences.org"},{"fact":"description","publisher":"terremotobiosciences.org","retrievedAt":"2026-05-08","status":"self-reported","url":"https://terremotobiosciences.org"}],"stage":null,"techStack":[],"totalRaisedUsd":41000000,"updatedAt":"2026-05-08"}